X @Bloomberg
Bloomberg·2026-05-07 20:08
Gilead said it now expects to book a loss in 2026 on $11.5 billion in charges after deals to acquire a string of companies making experimental cancer and autoimmune disease drugs https://t.co/VqTjk0MPkh ...
Gilead said it now expects to book a loss in 2026 on $11.5 billion in charges after deals to acquire a string of companies making experimental cancer and autoimmune disease drugs https://t.co/VqTjk0MPkh ...